Current therapy of acute heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute heart failure (AHF) presents with diverse pathophysiological mechanisms, commonly stemming from myocardial infarction, cardiomyopathy, or post-cardiac surgery.
• Mechanical defects like septal rupture or papillary muscle rupture necessitate surgical intervention.

Purpose of the Study:

• To outline therapeutic strategies for acute heart failure, emphasizing causal treatment and hemodynamic stabilization.
• To compare the efficacy and safety profiles of pharmacological agents used in AHF management.

Main Methods:

• Review of current therapeutic approaches for acute heart failure.
• Analysis of pharmacological agents, including dobutamine and amrinone, for hemodynamic management.
• Discussion of mechanical circulatory assist devices for temporary stabilization.

Main Results:

• Surgical correction is mandatory for mechanical defects.
• Mechanical circulatory assist devices can temporarily stabilize hemodynamics.
• Pharmacological therapy aims to relieve congestion and ensure tissue perfusion, balancing diuretics, vasodilators, and inotropes.
• Agents with combined vasodilatory and inotropic effects, like dobutamine and amrinone, are key.
• Amrinone demonstrates improved pump performance without increasing myocardial oxygen consumption, tolerance, or arrhythmogenicity compared to dobutamine.

Conclusions:

• Therapy for acute heart failure should be causally related and tailored to the patient's hemodynamic profile.
• Amrinone presents a favorable option for improving cardiac output in AHF due to its balanced effects and safety profile.